Androgen-Secreting Steroid Cell Tumor of the Ovary

Southern Medical Journal

Volumn 93, Issue 7-12, 2000, Pages 1201-1204

  Powell, John L ^a,b   Dulaney, David Paul ^a   Shiro, Brian C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b New Hanover Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LEUPRORELIN;

AGED; ARTICLE; CASE REPORT; FEMALE; GONADAL DISEASE; HUMAN; OVARY TUMOR; PATHOLOGY; SECRETION; SEX CORD TUMOR; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; LEUPROLIDE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SEX CORD-GONADAL STROMAL TUMORS; VIRILISM;

EID: 0034565706     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200093120-00012     Document Type: Article

References (25)

1. Young RH, Path FRC, Scully RE: Sex cord-stromal, steroid cell, and other ovarian tumors with endocrine, paraendocrine, and paraneoplastic manifestations. Blaustein's Pathology of the Female Genital Tract. Kurman RJ (ed). New York, Springer-Verlag, 1994, pp 783-847
2. Hayes MC, Scully RE: Ovarian steroid cell tumors (not otherwise specified): a clinicopathological analysis of 63 cases. Am J Surg Pathol 1987; 11:835-845
3. Bames RB, Ehrmann DA: Long-term suppression of testosterone after treatment with gonadotrapin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor. J Clin Endocrinol Metab 1997; 82:1746-1748
4. Wang PH, Chao HT, Lee WL: Use of a long-acting gonadotropin-releasing hormone agonist for treatment of steroid cell tumors of the ovary. Fertil Steril 1998; 69:353-355
5. Kennedy L, Traub A, Atkinson AB: Short term administration of gonadotropin releasing hormone analog to a patient with a testosterone secreting ovarian tumor. J Clin Endocrinol Metab 1987; 64:1320-1322
6. Steingold KA, Howard LJ, Neiberg RK, et al: Treatment of severe androgen excess due to ovarian hyperthecosis with long acting gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1986; 154:1241
7. Pascale MM, Pugeat M, Roberts M, et al: Androgen snppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumors. Clin Endocrinol 1994; 41:571-576
8. Martikainen H, Penttinen J, Huhtaniemi I, et al: Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy, Gynecol Oncol 1989; 35:406-408
9. Imai A, Lida K, Tamaya T: Direct action of gonadotropin-releasing honnone (LHRH) analogue on ovary: an alternative acting mechanism of buserelin. Arch Gynecol Obstet 1991; 248:117-121
10. Lux-Lantos VA, Thyssen SM, Chamson A, et al: Effect of a gonadotropin releasing hormone analog on an experimental ovarian tumor: direct and indirect actions. Life Sci 1995; 57:291-300
11. Yin H, Cheng KW, Hwa HL, et al: Expression of the messenger RNA for gonadotropinreleasing hormone and its receptor in human cancer cell lives. Life Sci 1998; 62:2015-2023
12. Emons G, Ortmann O, Becker M, et al: High affinity binding and direct antiproliferative effects of LHRH analogue in human ovarian cancer cell lines. Cancer Res 1993; 53:5439-5446
13. Takagi H, Imai A, Furui T, et al: Evidence for tight coupling kinase in plasma membrane from ovarian carcinomas. Gynecol Oncol 1995; 58:110-115
14. Palyi I, Vineze B, Kalnay A, et al: Effect of onadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lives. Cancer Detect Prevent 1996; 20:146-152
15. Vineze B, Palyi I, Gaal D, et al: In vivo studies of the new gonadotropin-releasing hormone antagonist-copolymer conjugates having antitumor activity. Cancer Detect Prevent 1996; 20:153-159
16. Ho MN, Delgado CH, Owens GA, et al: Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth. Fertil Steril 1997; 67:870-876
17. Imai A, Takagi A, Horibe S, et al: Evidence for light coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 1998; 83:427-431
18. Imai A, Takagi A, Horibe S, et al: Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 1996; 81:3249-3253
19. Imai A, Takagi A, Furui T, et al: Evidence for coupling of phosphotyrosine phospatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 1996; 77:132-137
20. Gershenson DM, Copeland LJ, Kavanaugh JJ, et al: Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol 1987; 70:765-769
21. Homesley HD, Bundy BN, Hureau JA, et al: Bleomycin, etoposide, and cisplatin (BEP) as first-line therapy of ovarian stromal malignancies. Gynecol Oncol 1998; 68:116
22. Yancik R, Ries LG, Yates JW: Ovarian cancer in the elderly: an analysis of surveillance, epidemiology and end results program data. Am J Obstet Gynecol 1986; 154:639-647
23. Fuctner C, Marietta A, Walker JL, et al: Radical hysterectomy in the elderly patient: analysis of morbidity. Am J Obstet Gynecol 1992; 166:593-597
24. Geisler JP, Geisler HI: Radical hysterectomy in patients 65 years of age and older. Gynecol Oncol 1994; 53:208-211
25. Cascinu S, Del Ferro E, Catalano G: Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996; 19:371-374